ADMA Biologics, Inc. (NASDAQ:ADMA) is now being followed by H.C. Wainwright, as they initiated the stock at Buy on February 07. Analysts at Maxim Group, maintained the company shares at Buy on December 11 but switched target price from $13 to $8. The stock won favor of Raymond James analysts who expressed their confidence in it using an upgrade from Mkt Perform to Outperform on November 14. Maxim Group analysts came out with bullish views on January 23 when the call was made. They think the stock is now Buy compared to to their prior call for Hold.
ADMA Biologics, Inc. (ADMA) hit an intraday high Tuesday at $3.75. The shares finished at $3.48, after trading as low as $3 earlier in the session. It rose 20.83% in recent trade and currently has a stock-market value of $152.01M. Trading activity significantly improved as the volume at ready counter increased to 3,968,240 shares versus 634,195 in average daily trading volume over the past 20 days. So far this year, the volume has averaged about 535,272 shares. The stock is now 67.31% above against its bear-market low of $2.08 on December 27, 2018. It has retreated -100% since it’s 52-week high of $6.96 reached in September. Now the market price is down -6.2% on the year and up 45.61% YTD.
ADMA’s 50 day simple moving average (SMA 50) price is $3.46 and its 200-day simple moving average (SMA 200) price is $4.95. The company’s stock currently has a total float of 29.61M shares. Its weekly volatility is hovering around 14.35% and felt 9.92% volatility in price over a month. On the upside, the share price will test short term resistance at around $3.82. On a downside, the stock is likely to find some support, which begins at $3.07. The failure to get near-term support could push it to $2.66.
Separately, it has been reported that multiple insider activity took place at ADMA Biologics, Inc. (ADMA). Director Richman Eric I acquired 5,230 shares for $36,530 in transaction occurred on 2018/06/08. After making this transaction, the Director owns a direct stake of 24,999 shares, worth $127,124, as per the last closing price. On 2018/06/08 Lenz Brian, VP, CFO at ADMA, purchased 5,000 shares at an average price of $4.78 per share. The new stake is valued at $69,600.
Director, Guiheen Lawrence P. had invested in 20,000 shares for $26,000 through a trade on 2018/06/08. Following this activity, the insider holds 95,600 shares worth $90,480 as of recent close. Wall Street’s most bullish ADMA Biologics, Inc. (NASDAQ:ADMA) analysts are predicting the share price to blow past $15 per share during the next 12 months. The current median share price forecast by them is $10, suggesting that the stock could increase 187.36% in that time frame. The average price target of $10.36 calls for a nearly 197.7% increase in the stock price.
Also, it is trading at rather expensive levels at just over 4.35x price/book and 6.1x price/sales. ADMA’s ROE is -159.4%, which is also considerably worse than the industry’s ROE of 10.21%. It’s also very liquid in the near term, with a current ratio of 6.3. The stock has a debt/capital of 1.18.
Shares of ADMA Biologics, Inc. (ADMA) have dropped -49.8% since the company’s last earnings report. Over the past 12 fiscal quarters, ADMA Biologics, Inc. (NASDAQ:ADMA) has topped consensus earnings estimates in 5 quarters (41%), missed earnings in 6 quarters (50%), whereas at 1 occasion EPS met analyst expectations. ADMA last reported earnings on November 08, 2018 when it released Sep-18 results that receded expectations. The company raked in -$0.33 per share, -94.88% change on the same period last year. That was worse than consensus for -$0.31. Revenue for the recent quarter stood at $4.23 million, down -11% on last year and below the $4.69 million predicted by analysts. For this quarter, Wall Street analysts forecast revenue in a range of $2.5 million to $6.91 million, which should be compared with $0 generated last year. EPS is seen in a range of -$0.26 to -$0.21, against the 0 reported a year ago.